FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006304925> ?p ?o ?g. }

• W2006304925 endingPage "174" @default.
• W2006304925 startingPage "169" @default.
• W2006304925 abstract "IL-33 activates eosinophils directly via the ST2 receptor. Like IL-5, IL-33 induces eosinophilia and eosinophilic airway inflammation in mouse models and primes human eosinophil responses. Previously, we reported that IL-5 priming enhances Siglec-8 mediated mitochondrial and reactive oxygen species (ROS)-dependent eosinophilic apoptosis and eliminates caspase dependence of this cell death process. Whether IL-33, like IL-5, augments pro-apoptotic pathways involving receptors such as Siglec-8 and in a similar manner has not been explored. Annexin-V labeling was performed to detect apoptosis in human eosinophils pre-incubated with or without a range of concentrations of IL-33 and/or IL-5 in the presence or absence of Siglec-8 monoclonal antibody (mAb) 2C4 and inhibitors of caspases. Tetramethyl-rhodamine staining was used as a marker of mitochondrial membrane potential loss and injury. ROS production was determined by measuring the superoxide dismutase-inhibitable reduction of cytochrome c. Cleavage of poly(ADP-ribose) polymerase (PARP) was assessed using Western blotting. Eosinophils cultured alone or with mAb 2C4 underwent low levels of apoptosis at 24h. 2C4-induced eosinophil apoptosis was markedly and equally enhanced after culture for 24h with either IL-33 or IL-5, although IL-5 was more potent. Effects on apoptosis with IL-33 and IL-5 were synergistic. In contrast, percentages of cells exhibiting reduced mitochondrial membrane potential were greater with IL-33 than IL-5 and effects of these cytokines were also synergistic. Antimycin, an inhibitor of mitochondrial electron transport, almost completely inhibited 2C4-induced apoptosis with either IL-33 or IL-5. Surprisingly, 2C4-induced eosinophil ROS production was significantly enhanced with IL-5 but not IL-33. Siglec-8-mediated apoptosis in the presence of IL-33 was more sensitive in magnitude than IL-5 to inhibition by the pan-caspase inhibitor Z-VAD-FMK, yet both cytokine conditions were associated with PARP cleavage. These data demonstrate that IL-33 is as effective but less potent than IL-5 in enhancing Siglec-8-mediated eosinophil apoptosis, and can synergize with IL-5. Eosinophils primed by IL-33 and/or IL-5 in vivo would be expected to display enhanced susceptibility to undergoing Siglec-8-induced apoptosis." @default.
• W2006304925 created "2016-06-24" @default.
• W2006304925 creator A5004888276 @default.
• W2006304925 creator A5028050069 @default.
• W2006304925 creator A5035725791 @default.
• W2006304925 date "2012-01-01" @default.
• W2006304925 modified "2023-10-13" @default.
• W2006304925 title "IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils" @default.
• W2006304925 cites W1591646293 @default.
• W2006304925 cites W1592281991 @default.
• W2006304925 cites W1766953595 @default.
• W2006304925 cites W1971907885 @default.
• W2006304925 cites W1978530217 @default.
• W2006304925 cites W1991042231 @default.
• W2006304925 cites W1997005484 @default.
• W2006304925 cites W2002474633 @default.
• W2006304925 cites W2026036357 @default.
• W2006304925 cites W2027246748 @default.
• W2006304925 cites W2032405768 @default.
• W2006304925 cites W2034634678 @default.
• W2006304925 cites W2050753573 @default.
• W2006304925 cites W2061298493 @default.
• W2006304925 cites W2062456152 @default.
• W2006304925 cites W2066248629 @default.
• W2006304925 cites W2077521688 @default.
• W2006304925 cites W2090509794 @default.
• W2006304925 cites W2100990833 @default.
• W2006304925 cites W2121210640 @default.
• W2006304925 cites W2124028447 @default.
• W2006304925 cites W2154872900 @default.
• W2006304925 cites W2157710399 @default.
• W2006304925 cites W2262618850 @default.
• W2006304925 doi "https://doi.org/10.1016/j.cyto.2011.10.007" @default.
• W2006304925 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3282301" @default.
• W2006304925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22079334" @default.
• W2006304925 hasPublicationYear "2012" @default.
• W2006304925 type Work @default.
• W2006304925 sameAs 2006304925 @default.
• W2006304925 citedByCount "68" @default.
• W2006304925 countsByYear W20063049252012 @default.
• W2006304925 countsByYear W20063049252013 @default.
• W2006304925 countsByYear W20063049252014 @default.
• W2006304925 countsByYear W20063049252015 @default.
• W2006304925 countsByYear W20063049252016 @default.
• W2006304925 countsByYear W20063049252017 @default.
• W2006304925 countsByYear W20063049252018 @default.
• W2006304925 countsByYear W20063049252019 @default.
• W2006304925 countsByYear W20063049252020 @default.
• W2006304925 countsByYear W20063049252021 @default.
• W2006304925 countsByYear W20063049252022 @default.
• W2006304925 countsByYear W20063049252023 @default.
• W2006304925 crossrefType "journal-article" @default.
• W2006304925 hasAuthorship W2006304925A5004888276 @default.
• W2006304925 hasAuthorship W2006304925A5028050069 @default.
• W2006304925 hasAuthorship W2006304925A5035725791 @default.
• W2006304925 hasBestOaLocation W20063049252 @default.
• W2006304925 hasConcept C104317684 @default.
• W2006304925 hasConcept C153911025 @default.
• W2006304925 hasConcept C182979987 @default.
• W2006304925 hasConcept C185592680 @default.
• W2006304925 hasConcept C190283241 @default.
• W2006304925 hasConcept C203014093 @default.
• W2006304925 hasConcept C2776042228 @default.
• W2006304925 hasConcept C2777037409 @default.
• W2006304925 hasConcept C31573885 @default.
• W2006304925 hasConcept C48349386 @default.
• W2006304925 hasConcept C55493867 @default.
• W2006304925 hasConcept C82381507 @default.
• W2006304925 hasConcept C86803240 @default.
• W2006304925 hasConcept C95444343 @default.
• W2006304925 hasConcept C98424977 @default.
• W2006304925 hasConceptScore W2006304925C104317684 @default.
• W2006304925 hasConceptScore W2006304925C153911025 @default.
• W2006304925 hasConceptScore W2006304925C182979987 @default.
• W2006304925 hasConceptScore W2006304925C185592680 @default.
• W2006304925 hasConceptScore W2006304925C190283241 @default.
• W2006304925 hasConceptScore W2006304925C203014093 @default.
• W2006304925 hasConceptScore W2006304925C2776042228 @default.
• W2006304925 hasConceptScore W2006304925C2777037409 @default.
• W2006304925 hasConceptScore W2006304925C31573885 @default.
• W2006304925 hasConceptScore W2006304925C48349386 @default.
• W2006304925 hasConceptScore W2006304925C55493867 @default.
• W2006304925 hasConceptScore W2006304925C82381507 @default.
• W2006304925 hasConceptScore W2006304925C86803240 @default.
• W2006304925 hasConceptScore W2006304925C95444343 @default.
• W2006304925 hasConceptScore W2006304925C98424977 @default.
• W2006304925 hasFunder F4320332161 @default.
• W2006304925 hasIssue "1" @default.
• W2006304925 hasLocation W20063049251 @default.
• W2006304925 hasLocation W20063049252 @default.
• W2006304925 hasLocation W20063049253 @default.
• W2006304925 hasLocation W20063049254 @default.
• W2006304925 hasOpenAccess W2006304925 @default.
• W2006304925 hasPrimaryLocation W20063049251 @default.
• W2006304925 hasRelatedWork W1670069535 @default.
• W2006304925 hasRelatedWork W2016968094 @default.
• W2006304925 hasRelatedWork W2021693564 @default.
• W2006304925 hasRelatedWork W2029405692 @default.

• next